As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples, the Pentagon said.» Read More
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
Meg Tirrell tells us why the future of cancer therapy may almost be here.
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
Health insurer Humana has received takeover interest, with potential bidders including Aetna and Cigna, according to reports.
As the government program reaches the half-century mark, it needs to get into the digital age, says this University of Rochester professor.
Congressional Republicans have yet to act on plans to deal with the potential loss of subsidies for HealthCare.gov customers.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
When it comes to planning for long-term health-care costs, the rich are a lot like most Americans—they haven't given it much thought.
Health care giant Johnson & Johnson has formally accepted a $1.94 billion offer to sell its Cordis heart devices unit to Cardinal Health.
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
The Affordable Care Act will add $273.6 billion in insurance administrative overhead costs from 2012 to 2022, a new report says.
Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.
Jawbone is suing Fitbit and a group of employees who quit Jawbone, saying they stole trade secrets, business plans, and market research.
The Pentagon said a military facility that mistakenly anthrax to nine states had been trying to develop a test to identify biological threats.
The FBI is looking into what Johnson & Johnson knew about the risks posed by a surgical tool, according to a report by the WSJ.
The first report from a big public-private project to improve genetic testing reveals it is not as rock solid as many people believe.
The White House called for further review from the scientific community on human genome editing in a note issued Tuesday.
Worried about having too many drinks on a work night? A study suggests that this isn’t such a big deal for your productivity, but rather sleep.
In the world's fight against antibiotic resistance, Bayer CEO Marijn Dekkers sees the need for a global antibiotics bailout.
Get the best of CNBC in your inbox